Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center
News provided by
Share this article
Share this article
TOKYO, Jan. 14, 2021 /PRNewswire/ FUJIFILM Corporation (COO: Kenji Sukeno) and the Center for Advanced Biological Innovation and Manufacturing (CABIM), today announced that it has secured $76 million in financing and signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at
The Arsenal on the Charles, owned and operated by Alexandria Real Estate Equities, Inc. The Center will advance research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. FUJIFILM Diosynth Biotechnologies, the Bio CDMO
The Massachusetts Center for Advanced Biological Innovation and Manufacturing has obtained $76 million in funding and signed a lease for a 40,000-square foot site in Watertown, Mass. for the manufacturing and innovation of new biotechnologies, it announced in a press release Thursday.
A public-private partnership led by Harvard and the Massachusetts Institute of Technology, CABIM was formed in late 2019 to foster partnerships between academics, biopharma, and medical leaders to accelerate the production and delivery of new treatment technologies to patients.
Harvard led the fundraising effort, along with other founding members of CABIM including MIT, FUJIFILM Diosynth Biotechnologies, Cytiva, and Alexandria Real Estate Equities, Inc., which owns and operates the business park where the center will be located, called The Arsenal on the Charles.
State of Alaska Department of Revenue Purchases 2,181 Shares of Alexandria Real Estate Equities, Inc (NYSE:ARE) forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
PASADENA, Calif., Jan. 8, 2021 /PRNewswire/ Alexandria Real Estate Equities, Inc. ( Alexandria or the Company ) (NYSE: ARE) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of the Company s common stock at a public offering price of $164.00 per share, including the 900,000 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares of the Company s common stock. In connection with the offering, the Company entered into forward sale agreements, between the Company and each of JPMorgan Chase Bank, N.A., Bank of America, N.A., Citibank, N.A., Goldman Sachs & Co. LLC and Royal Bank of Canada (together, the forward purchasers ).
Five things you need to know today, and I m heartbroken today bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.